West Pharmaceutical Services, Inc.· WST
🇺🇸 US · LargeSP500NYSE
- Price
- $339.97
- Day
- -0.81%
- Mkt Cap
- $23.93B
- 52W Range
- $223.83 – $386.00
- Volume
- 337.8K
- Beta
- 1.14
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Analyzing West Pharmaceutical Services (NYSE:WST) and Acutus Medical (NASDAQ:AFIB)
West Pharmaceutical Services (NYSE: WST - Get Free Report) and Acutus Medical (NASDAQ: AFIB - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends. Volatility and Risk West Pharmaceutical Services has
Benjamin Edwards Inc. Grows Position in West Pharmaceutical Services, Inc. $WST
Benjamin Edwards Inc. grew its stake in West Pharmaceutical Services, Inc. (NYSE: WST) by 47.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,322 shares of the medical instruments supplier's stock after buying an additional 1,720 shares
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Recommendation of “Moderate Buy” from Brokerages
West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the
7,730 Shares in West Pharmaceutical Services, Inc. $WST Bought by Caisse de depot et placement du Quebec
Caisse de depot et placement du Quebec purchased a new stake in West Pharmaceutical Services, Inc. (NYSE: WST) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,730 shares of the medical instruments supplier's stock, valued at approximately $2,775,000. Several
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.